ResultsIQ

ResultsIQ › Latest results › Healthcare Global Enterprises Limited

Healthcare Global Enterprises Limited Q3 FY26 results deck summary

NSE: HCG · BSE: 539787

Results deck of 5 Feb 2026, summarised by AI from the filing.

Q3FY26 revenue ₹6,331 mn (+13% YoY) and Adjusted EBITDA ₹1,108 mn (+20% YoY); North Bangalore hospital operations expected by end of Q4FY26.

Key takeaways

  1. Revenue Q3FY26 revenue ₹6,331 mn (Q3FY25: ₹5,586 mn, +13% YoY), with broad-based growth across clusters.
  2. Adjusted EBITDA Q3FY26 Adjusted EBITDA ₹1,108 mn (Q3FY25: ₹923 mn, +20% YoY); margin 17.5% (Q3FY25: 16.5%).
  3. North Bangalore North Bangalore Greenfield Hospital operations expected to commence by the end of Q4FY26, first in Bangalore to offer MR-LINAC.
  4. Growth driver West cluster revenue grew ~17% YoY, supported by strong volumes including the expanded hospital in Ahmedabad.

Original filing on BSE

Healthcare Global Enterprises Limited Q1 FY27 results

As filed: Revenue ₹695 cr (+13% year on year), EBITDA ₹122 cr (+14% year on year), PAT ₹16.5 cr (+174% year on year), EBITDA margin 17.6% (+13 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹652 cr (+12% year on year), EBITDA ₹125 cr (+18% year on year), PAT ₹4.0 cr (+133% year on year), EBITDA margin 19.2% (+105 bps). Score 48 of 100, In line with trend. Revenue growth was below the company's own trend; EBITDA growth was in line with it; profit before exceptional items growth was well above it. EBITDA margin rose 105 bps year on year. Other income 1790% of PBT. Tax rate -382%. Revenue rose ₹67.3 cr on a year ago, against ₹90.0 cr the year before. Share price after the results: −5.0% in 30 days (Nifty 500: +3.0%).
  • Q3 FY26: Revenue ₹633 cr (+13% year on year), EBITDA ₹110 cr (+25% year on year), PAT −₹7.9 cr, EBITDA margin 17.3% (+154 bps). Score 65 of 100, Above trend. Revenue growth was below the company's own trend; EBITDA growth was well above it. EBITDA margin rose 154 bps year on year. Profit fell 67% from last quarter. Revenue rose ₹75.1 cr on a year ago, against ₹88.0 cr the year before. Share price after the results: −1.8% in 30 days (Nifty 500: +0.4%).
  • Q2 FY26: Revenue ₹647 cr (+17% year on year), EBITDA ₹124 cr (+20% year on year), PAT ₹21.0 cr (0% year on year), EBITDA margin 19.2% (+57 bps). Score 49 of 100, In line with trend. Revenue and EBITDA growth were above the company's own trend; profit growth was below it. EBITDA margin rose 57 bps year on year. Tax rate -5%. Consolidated profit +0% but standalone -31%. Revenue rose ₹93.0 cr on a year ago, more than the ₹67.0 cr it added the year before. Share price after the results: −4.4% in 30 days (Nifty 500: −0.5%).
  • Q1 FY26: Revenue ₹613 cr (+17% year on year), EBITDA ₹107 cr (+18% year on year), PAT ₹6.0 cr (−57% year on year), EBITDA margin 17.5% (+15 bps). Score 38 of 100, Below trend. Revenue growth was above the company's own trend; EBITDA growth was in line with it; profit growth was well below it. EBITDA margin rose 15 bps year on year. Other income 64% of PBT. Tax rate 55%. Profit fell 14% from last quarter. Revenue rose ₹87.0 cr on a year ago, more than the ₹65.0 cr it added the year before. Share price after the results: +12.2% in 29 days (Nifty 500: −4.7%).
  • Q4 FY25: Revenue ₹585 cr (+18% year on year), EBITDA ₹106 cr (+15% year on year), PAT ₹7.0 cr (−70% year on year), EBITDA margin 18.1% (−47 bps). Score 37 of 100, Below trend. Revenue growth was above the company's own trend; EBITDA growth was in line with it; profit growth was well below it. EBITDA margin fell 47 bps year on year. Other income 71% of PBT. Tax rate 50%. Profit fell 13% from last quarter. Revenue rose ₹90.0 cr on a year ago, more than the ₹53.0 cr it added the year before. Share price after the results: −11.1% in 30 days (Nifty 500: +1.0%).
  • Q3 FY25: Revenue ₹558 cr (+19% year on year), EBITDA ₹88.0 cr (+13% year on year), PAT ₹8.0 cr (+167% year on year), EBITDA margin 15.8% (−83 bps). Score 52 of 100, In line with trend. Revenue growth was well above the company's own trend; EBITDA growth was below it; profit growth was in line with it. EBITDA margin fell 83 bps year on year. Consolidated profit +167% but standalone -562%. Profit fell 62% from last quarter. Revenue rose ₹88.0 cr on a year ago, more than the ₹45.0 cr it added the year before.
  • Q2 FY25: Revenue ₹554 cr (+14% year on year), EBITDA ₹103 cr (+21% year on year), PAT ₹21.0 cr (+91% year on year), EBITDA margin 18.6% (+114 bps). Score 64 of 100, In line with trend. EBITDA margin rose 114 bps year on year. Other income 39% of PBT. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Healthcare Global Enterprises Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.